10.26.26 -- On The Ground At BPI: Jacqualyn Schulman, Ph.D., On Accelerating Clonal CLD

Uncover how tighter alignment between vector construction and cell banking improved development efficiency, strengthened risk management, and enhanced early-stage program outcomes.

Explore how intensified perfusion strategies enable rapid, high‑density CAR‑T expansion, predictive scale‑down modeling, and efficient automated harvest, supporting shorter timelines and higher yields.

Discover how automating cell banking workflows minimizes contamination risks and preserves viability in high-density cultures, ensuring consistent recovery and smoother scale-up.

See how automated screening can accelerate CLD while preserving selection confidence, identifying promising candidates that manual methods may miss, and predicting poor fed-batch performers.

Review a novel adenovirus production process that offers scalable, single-use equipment-compatible solutions, reducing production time and cross-contamination risks.

Monoclonal antibody therapies are reshaping breast cancer treatment. Examine the latest manufacturing advances and research solutions helping developers accelerate therapy production at every stage.

Learn about a feeder-free method to differentiate CD8+ single positive T cells from human induced pluripotent stem cells, which offers promising advancements for scalable and efficient cell therapies.

Find out how whether you’re trying to achieve speed and cost-effectiveness or higher yields and glycosylation capabilities, the right system can be tailored to meet the needs of each unique biologic.

A high-performance, helper virus-free stable producer cell line is derived from proprietary high-producer HEK293 cells and is cultivated in a chemically defined, serum-free, ADCF medium in suspension.

Access a phased, risk-minimized integration framework to scale your enzymatic post-production process seamlessly from initial lab-scale feasibility up to commercial GMP readiness.